Candel Therapeutics (CADL) Assets (2020 - 2025)

Candel Therapeutics (CADL) has 6 years of Assets data on file, last reported at $125.2 million in Q4 2025.

• For the quarter ending Q4 2025, Assets rose 17.15% year-over-year to $125.2 million; the trailing twelve-month figure through Dec 2025 stood at $125.2 million (up 17.15% YoY), and the FY2025 full-year result was $125.2 million, up 17.15% from the prior year.
• Assets advanced to $125.2 million in Q4 2025, from $93.6 million in the prior quarter.
• In the past five years, Assets ranged from a high of $125.2 million in Q4 2025 to a low of $21.5 million in Q3 2024.
• A 5-year average of $73.5 million and a median of $85.0 million in 2022 frame the typical range for Assets.
• Across the five-year window, Assets slumped 57.02% in 2024 and surged 335.0% in 2025, its largest moves.
• Tracing CADL's Assets over 5 years: stood at $89.2 million in 2021, then retreated by 12.91% to $77.7 million in 2022, then sank by 46.97% to $41.2 million in 2023, then surged by 159.38% to $106.9 million in 2024, then rose by 17.15% to $125.2 million in 2025.
• Business Quant data shows CADL's Assets at $125.2 million in Q4 2025, $93.6 million in Q3 2025, and $106.0 million in Q2 2025.